| Title: |
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD : a multicentre study |
| Authors: |
Siriratnam, Pakeeran; Sanfilippo, Paul; van der Walt, Anneke; Sharmin, Sifat; Foong, Yi Chao; Yeh, Wei Zhen; Zhu, Chao; Khoury, Samia Joseph; Csepany, Tunde; Willekens, Barbara; Etemadifar, Masoud; Ozakbas, Serkan; Nytrova, Petra; Altintas, Ayse; Al-Asmi, Abdullah; Yamout, Bassem; Laureys, Guy; Patti, Francesco; Simo, Magdolna; Surcinelli, Andrea; Foschi, Matteo; McCombe, Pamela A; Alroughani, Raed; Sánchez-Menoyo, José Luis; Turkoglu, Recai; Soysal, Aysun; Lechner Scott, Jeanette; Kalincik, Tomas; Butzkueven, Helmut; Jokubaitis, Vilija; Huda, Saif; Monif, Mastura; Van Hijfte, Liesbeth; MSBASE study group, missing |
| Source: |
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY ; ISSN: 0022-3050 ; ISSN: 1468-330X |
| Publication Year: |
2025 |
| Collection: |
Ghent University Academic Bibliography |
| Subject Terms: |
Medicine and Health Sciences; Biology and Life Sciences; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; IMMUNOLOGY; MEDICINE; HEALTH ECONOMICS; OPTICA SPECTRUM DISORDER; NEUROMYELITIS-OPTICA; DOUBLE-BLIND; EFFICACY; SAFETY; AZATHIOPRINE; SATRALIZUMAB; RITUXIMAB; OUTCOMES |
| Description: |
Background Neuromyelitis optica spectrum disorder (NMOSD) can be categorised into aquaporin-4 antibody (AQP4-IgG) NMOSD or seronegative NMOSD. While our knowledge of AQP4-IgG NMOSD has evolved significantly in the past decade, seronegative NMOSD remains less understood. This study aimed to evaluate the predictors of relapses and treatment responses in AQP4-IgG NMOSD and seronegative NMOSD. Methods This was a multicentre, international, retrospective cohort study using the MSBase registry. Recurrent relapse risk was assessed using an Andersen-Gill model and risk of first relapse was evaluated using a Cox proportional hazards model. Covariates that putatively influence relapse risk included demographic factors, clinical characteristics and immunosuppressive therapies; the latter was assessed as a time-varying covariate. Results A total of 398 patients (246 AQP4-IgG NMOSD and 152 seronegative NMOSD) were included. The AQP4-IgG NMOSD and seronegative NMOSD patients did not significantly differ by age at disease onset, ethnicity or annualised relapse rate. Both low-efficacy and high-efficacy immunosuppressive therapies were associated with significant reductions in recurrent relapse risk, with notably greater protection conferred by high-efficacy therapies in both AQP4-IgG NMOSD (HR 0.27, 95% CI 0.15 to 0.49, p |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
https://biblio.ugent.be/publication/01J717RMKZ2EYN5W9S93Y4CQZX; https://biblio.ugent.be/publication/01J717RMKZ2EYN5W9S93Y4CQZX/file/01J737BYHNM5R696JH6VKC1ZET |
| DOI: |
10.1136/jnnp-2024-334090 |
| Availability: |
https://biblio.ugent.be/publication/01J717RMKZ2EYN5W9S93Y4CQZX; https://hdl.handle.net/1854/LU-01J717RMKZ2EYN5W9S93Y4CQZX; https://doi.org/10.1136/jnnp-2024-334090; https://biblio.ugent.be/publication/01J717RMKZ2EYN5W9S93Y4CQZX/file/01J737BYHNM5R696JH6VKC1ZET |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.2BDE3EAC |
| Database: |
BASE |